CN1326745A - Montmorillonite as component of gastrointestinal tract medicine - Google Patents

Montmorillonite as component of gastrointestinal tract medicine Download PDF

Info

Publication number
CN1326745A
CN1326745A CN00109389A CN00109389A CN1326745A CN 1326745 A CN1326745 A CN 1326745A CN 00109389 A CN00109389 A CN 00109389A CN 00109389 A CN00109389 A CN 00109389A CN 1326745 A CN1326745 A CN 1326745A
Authority
CN
China
Prior art keywords
mineral
montmorillonitum
writing
dioctahedron
put down
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00109389A
Other languages
Chinese (zh)
Inventor
翟永功
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wang Yingdian
Zuo Mingxue
Original Assignee
Wang Yingdian
Zuo Mingxue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wang Yingdian, Zuo Mingxue filed Critical Wang Yingdian
Priority to CN00109389A priority Critical patent/CN1326745A/en
Publication of CN1326745A publication Critical patent/CN1326745A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the application of montmorillonite as the component of the medicines for preventing and treating diarrhea and other gastrointestinal tract diseases. The medicines include Chinese medicine, Chinese and Western medicine, medicine supplementary material, carrier, and controlled releasing agent. Montmorillonite is a kind of silicate mineral comprising regularly stacked structural units of two tetrahedron layers and one sandwiched octahedron layer.

Description

Montmorillonitum is the composition of gastrointestinal drug
The present invention relates to the composition of a kind of mineral Montmorillonitum, be used for the treatment of and/or prevent the medicine and the preparation of the acute and chronic diarrhoeal diseases of humans and animals and other gastroenteropathy as gastrointestinal drug and anti-diarrheal.Montmorillonitum as a kind of pharmaceutical compositions, is used for the treatment of and prevents diarrhoea property disease and other gastroenteropathy, is pharmacy allusion quotation collection, Compendium of Material Medica, " all not on the books in the Chinese pharmacopoeia since ancient times.The present invention relates to the pharmaceutical characteristic of Montmorillonitum to diarrhoeal diseases and other gastrointestinal mucosa disease, is to determine by the textual criticism of mineral drug kind, mineral drug component analysis and mineral drug evaluation, animal pharmacology and clinical test results.
Prior art: according to statistics, developing country's diarrhoeal diseases will be seized 4,000,000 babies' life every year.In decades before, diarrhoea property treatment of diseases is mainly relied on antibiotic, since nineteen twenty-nine Fleming finds penicillin, constantly had new antibiotic to come out, found 4000 at present surplus kind of antibiotic, be used for clinical down over one hundred kind.Antibiotic application is controlled most of bacteroidal diseases.But because the life-time service antibiotic can make pathogen sport Resistant strain, develop immunity to drugs, simultaneously, also can cause the imbalance of humans and animals body normal flora, and the formation of the organism immune response of drawing up.WHO diarrhoea group proposes, and 90% diarrhoea does not need to use antibiotic therapy.Domestic scholars is according to the composition and the clinical observation of China's diarrhoea pathogenic spectrum, and proving in China does not need to account for 70% with the diarrhoeal diseases of antibiotic therapy.But present clinical antibiotic utilization rate reaches 50%-100%, and nineteen ninety statistical average is 84%.Its consequence is to cause bacterial drug resistance to strengthen, and the normal intestinal flora disorder has destroyed the microecological balance of intestinal, making the diarrhoea delay or increases the weight of.Domestic expert is consistent to think that about 70% watery stool diarrhoea, can be without antibiotic therapy for virus or produce malicious antibacterial and cause.
The generation of diarrhoeal diseases removes outside the Pass quantity, virulence, field planting ability with pathogenic microorganism (antibacterial, virus etc.) have, and is also closely related with nutrition, immune system (comprising nonspecific barrier functions such as gastric acid, enterokinesia, intestinal microbial population and mucus quality) and the specific immune material (SIgA) of body.Therefore, the even more important treatment measure of antagonism diarrhoeal diseases attack factor is a physiological function of recovering and safeguard the intestinal mucosa barrier, and this will be one of the recent tendency in the field of diarrhoeal diseases treatment from now on.What this patent was related is the mineral drug of main component with the Montmorillonitum; exactly to recover and to safeguard the barrier function of intestinal mucosa; with its unique physical and chemical performance antagonism diarrhoeal diseases attack factor; its active component can combine with the intestinal mucous glycoprotein; strengthen the defencive function of mucosal barrier, thereby make it have the function of treatment diarrhoeal diseases and other gastroenteropathy.
Purpose: with the composition of Montmorillonitum as diarrhea medicine and other gastrointestinal drug, can be the natural gastrointestinal tract new drug that initiative has China's independent intellectual property rights, alternative antibiotic is used for diarrhoeal diseases and other gastrointestinal mucosa treatment of diseases and prevention.
Technical scheme: Montmorillonitum is a kind of mineral drug; with it is diarrhea medicine and other gastrointestinal drug of composition development; the toxin that has the virus in the digestive tract, pathogenic bacteria and generation thereof has the extremely strong effect of fixing, draw up; gastrointestinal mucosal there is very strong barrier protection function; its unique chemical constituent that contains can interact with the mucous glycoprotein in the intestinal mucosa cell, strengthens the barrier protection function of intestinal mucosa.Simultaneously, Montmorillonitum can play the enhancing drug effect and reduce medicine to gastrointestinal tract mucous stimulation as the controlled release fertilizer agent of other gastrointestinal drug.
Technological merit: is diarrhea medicine and other gastrointestinal drug of main component with the Montmorillonitum, in the treatment of diarrhoeal diseases and other gastroenteropathy, does not enter blood circulation, have no side effect, drug residue free; Montmorillonitum can reduce the zest medicine to the gastrointestinal side effect.Therefore, Montmorillonitum diarrhea mineral drug is brand-new green gastrointestinal tract new drug.
Technology path: select natural montmorillonite mineral raw material,, can obtain the Montmorillonitum of medicinal standard by certain process for separating and purifying.For some particular components of purification, used chemical drugs and reagent also all are very common common drugs.The discrimination method of Montmorillonitum also is that sensation, fracture, hardness, proportion of character, appearance color, gloss, hands tongue according to mineral etc. done general discriminating, and then application modern analysis means, its chemical composition and structure are analyzed, measured its distinctive physical and chemical performance simultaneously.
Description of drawings: the crystal structure sketch map of the X of main chemical composition Fig. 2 Montmorillonitum of Fig. 1 Montmorillonitum-x ray diffration pattern x Fig. 3 Montmorillonitum

Claims (6)

1, a kind of mineral Montmorillonitum is used to prepare gastrointestinal drug, and anti-diarrheal and other are used for the treatment of the medicine or the preparation of mucosal disease, it is characterized in that:
(1) a kind of layered clay mineral has the dioctahedron architectural feature;
(2) the dioctahedron layer thickness has certain variation;
(3) basic chemical composition is silicate or aluminosilicate;
(4) outward appearance is earthy, the tool soapy feeling;
(5) have intensive water absorption and dilatancy;
(6) toxin to antibacterial, virus and generation thereof has fixing, the effect of adsorbing, draw up, and mucosa is had the barrier protection effect;
2, the mineral Montmorillonitum of putting down in writing according to claim 1, its English name: montmorillonite, another name: montmorillonitic clay, Montmorillonitum family, it is characterized in that said dioctahedron is formed structural units's layer by two tetrahedral layers and an octahedral layer that is clipped in the middle in (1), repeat to stack into crystal regularly from level to level by this Institutional Layer again, form the dioctahedron structure;
3, according to claim 1,2 mineral of being put down in writing, it is characterized in that said dioctahedron structure sheaf has certain thickness in (2), layer thickness can change basal spacing d because of the content of intermediary water, the kind difference of interlayer ion 001=1.200~1.800nm;
4,, it is characterized in that said basic chemical composition is silicate or aluminosilicate in (3), its main chemical compositions: SiO according to claim 1,2,3 mineral of being put down in writing 240.0~80.0%, AL 2O 312.0~25.0%, Fe 2O 31.00-5.00% in addition, often contains multiple elements such as P, K, Na, Ca, Mg, Al, Fe, Mn, Cu, zn, Li, Ti, V, Cr;
5, according to claim 1,2,3,4 mineral of being put down in writing, it is characterized in that said Montmorillonitum outward appearance often is earthy in (4), sometimes be tiny scale aggregate, be white in color, but, often be light gray, tone such as greyish white, pink, light green because of often containing multiple elements such as P, K, Na, Ca, Mg, Al, Fe, Mn, Cu, Zn, Li, Ti, V, Cr; Tarnish when dry, very soft, the tool soapy feeling; Have intensive water absorption and dilatancy; Be suspended state and gelatinized in the aqueous solution or become pastel;
6,, it is characterized in that said Montmorillonitum can adsorb in (6), the toxin of fix, draw up harmful pathogenic bacteria and generation thereof in gastrointestinal tract according to claim 1,2,3,4,5 mineral of being put down in writing; Repair and the protection mucosa, have the effect of prevention and treatment diarrhoeal diseases and other gastroenteropathy.
CN00109389A 2000-06-01 2000-06-01 Montmorillonite as component of gastrointestinal tract medicine Pending CN1326745A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN00109389A CN1326745A (en) 2000-06-01 2000-06-01 Montmorillonite as component of gastrointestinal tract medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN00109389A CN1326745A (en) 2000-06-01 2000-06-01 Montmorillonite as component of gastrointestinal tract medicine

Publications (1)

Publication Number Publication Date
CN1326745A true CN1326745A (en) 2001-12-19

Family

ID=4579607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00109389A Pending CN1326745A (en) 2000-06-01 2000-06-01 Montmorillonite as component of gastrointestinal tract medicine

Country Status (1)

Country Link
CN (1) CN1326745A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605551A (en) * 2007-02-06 2009-12-16 益普生制药股份有限公司 The application of clay in the treatment celiac disease
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US8106000B2 (en) 2005-05-18 2012-01-31 Da Volterra Colonic delivery of adsorbents
US8956664B2 (en) 2011-10-20 2015-02-17 Salient Pharmaceuticals Incorporated Methods and compositions for treating mucositis
CN101686997B (en) * 2006-06-27 2016-03-16 德克萨斯肠吸附剂公司 Calcium aluminosilicate pharmaceutical
CN105520954A (en) * 2010-04-29 2016-04-27 益普生制药股份有限公司 Clay compositions
US9597313B2 (en) 2006-06-27 2017-03-21 Timothy D. Phillips Composition and methods for the enterosorption and management of toxins

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106000B2 (en) 2005-05-18 2012-01-31 Da Volterra Colonic delivery of adsorbents
CN101257892B (en) * 2005-05-18 2013-01-02 达沃尔泰拉公司 Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US8388984B2 (en) 2006-05-17 2013-03-05 Da Volterra Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CN101686997B (en) * 2006-06-27 2016-03-16 德克萨斯肠吸附剂公司 Calcium aluminosilicate pharmaceutical
US9597313B2 (en) 2006-06-27 2017-03-21 Timothy D. Phillips Composition and methods for the enterosorption and management of toxins
CN101605551A (en) * 2007-02-06 2009-12-16 益普生制药股份有限公司 The application of clay in the treatment celiac disease
CN101605551B (en) * 2007-02-06 2013-04-03 益普生制药股份有限公司 Use of a clay to prepare a medicament for treating or preventing coeliac disease
CN105520954A (en) * 2010-04-29 2016-04-27 益普生制药股份有限公司 Clay compositions
US8956664B2 (en) 2011-10-20 2015-02-17 Salient Pharmaceuticals Incorporated Methods and compositions for treating mucositis

Similar Documents

Publication Publication Date Title
CN1843499A (en) Traditional Chinese medicine formulation for treating bronchitis and tonsillitis
CN1326745A (en) Montmorillonite as component of gastrointestinal tract medicine
CN104225246B (en) A kind of canker sore film and preparation method thereof
CN1698648A (en) Montmorillonite dispersed tablet and preparation technique thereof
Khakoo et al. Effect of inosiplex (Isoprinosine®) on induced human influenza A infection
CN1682895A (en) Medicine for relieving asthma and cough and its preparing method
CN100579557C (en) Cough-stopping granule with honeysuckle flower and bulbus fritilariae
CN1326746A (en) Montmorilonite as component of animal medicine and fodder additive
CN103285396A (en) Medicine composition for eradicating helicobacter pylori, as well as preparation method and application
CN101773573B (en) Chinese medicine composition for treating infantile diarrhea
CN1559508A (en) Medicine for preventing and curing laryngolaryngitis and its preparation method
CN1150927C (en) Stomatopathy and throat disease treating health care medicine and its production process
CN101757083B (en) Costunolide-containing traditional Chinese medicine composition for treating gastrointestinal diseases and preparation method thereof
CN1051009C (en) Chinese drug for treating chronic colitis
Bernoville Diseases of the Respiratory & Digestive System of Children
CN1081374A (en) The Radix Pseudostellariae treatment of cough and asthma
CN1329072C (en) Medicine for treating infant's fever and cough and preparing method
WO2018034457A1 (en) Composition for preventing or treating mental disorder, containing lactobacillus sp. bacteria-derived vesicle
CN109700833A (en) A kind of pharmaceutical composition and its preparation method and application for treating constipation
Wilkinson Helicobacter pylori: an overview
CN102058799A (en) Chinese medicinal composition for eliminating phlegm and stopping cough
CN103127509A (en) Medicine composition and preparation method and purpose
CN1172696C (en) Medicine for preventing acute upper respiratory tract infection of children group
CN1111417C (en) Compound tablet 'Changning' and its preparing process
CN1318069C (en) Shuanghuang Zhenbei powder medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication